Search

EHA-SWG Scientific Meeting “Developing a research agenda for transfusion in Europe”

On September 15-17, 2022, the EHA-SWG Scientific Meeting “Developing a research agenda for transfusion in Europe” was successfully held at the Occidental Praha hotel in Prague, Czechia.

Read more

A new form of inherited thrombocytopenia (ETV6-related thrombocytopenia, ETV6-RT): NEVER JUDGE A BOOK BY ITS COVER!

A new form of inherited thrombocytopenia (ETV6-related thrombocytopenia, ETV6-RT): NEVER JUDGE A BOOK BY ITS COVER!

We recently discovered a new form of an inherited deficiency of platelets (inherited thrombocytopenia-IT), which is caused by mutations in the ETV6-gene.

Read more

Alliances & partnerships

EHA's approach to policy and regulatory affairs involves collaboration across medical professions and disciplines.

Read more

Highlights of Past EHA (HOPE) EMEA 2020

Highlights of Past EHA (HOPE) EMEA 2020
October 9-10, 2020
Meeting Chairs:

Prof J Gribben (European Hematology Association)
Prof GH Özsan

In the second weekend of October, EHA and the Turkish Society of Hematology (TSH) kicked-off the very first virtual HOPE meeting.…

Read more

Lighting the Flame program phases

A full guide to what our Lighting the Flame program involves, including dates of upcoming online workshops and in-person retreats.

Read more

I4MDS consortium: advancing MDS treatment and understanding

The role of the immune system in the pathophysiology of Myelodysplastic Neoplasms (MDS) is firmly established. However, routine immune monitoring for these patients is still not a common practice.

Read more

Login

EHA membership area login (MyEHA)

Please use your e-mail address and password to login to your EHA membership area.

Read more

International CML adherence survey launched

The drivers behind non-adherence, a highly prevalent problem in oral cancer treatments but also in many other diseases like diabetes, are not well understood to date.

Read more

Treatment and survival of patients with chronic myeloid leukemia (CML) in Europe

Since the introduction of tyrosine kinase inhibitors into the treatment of CML survival times have greatly improved.

Read more